We’ve developed a low-dose, low-volume H5N1 intranasal ferret challenge model to advance influenza antiviral and vaccine research. Using only 50 µL per nare and 100 TCID50 of H5N1. This physiologically relevant approach avoids the FDA’s concerns with high-dose models.
#Influenza #ArtemisBiosciences